Article info

Download PDFPDF
Is There a High-Risk Subgroup of Stage I Epithelial Ovarian Cancer that Is Most Likely to Benefit From 6 Versus 3 Cycles of Adjuvant Chemotherapy?

Authors

  1. Address correspondence and reprint requests to Jamie N. Bakkum-Gamez, MD, Division of Gynecologic Surgery, Mayo Clinic, 200 1st St SW, Rochester, MN 55905. E-mail: bakkum.jamie{at}mayo.edu.

Citation

Bakkum-Gamez JN, Richardson DL, Seamon LG, et al
Is There a High-Risk Subgroup of Stage I Epithelial Ovarian Cancer that Is Most Likely to Benefit From 6 Versus 3 Cycles of Adjuvant Chemotherapy?

Publication history

  • Received February 15, 2010
  • First published October 1, 2010.
Online issue publication 
October 01, 2010

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.